| Literature DB >> 28374236 |
Shwetha Chiplunkar1,2, Parayil Sankaran Bindu3,4, Madhu Nagappa2,5, Bobby Baby Panikulam5, Hanumanthapura R Arvinda6, Periyasamy Govindaraj2,5, M M Srinivas Bharath7, Narayanappa Gayathri2,8, J N Jessiena Ponmalar2, Pavagada S Mathuranath5, Sanjib Sinha5, Arun B Taly2,5.
Abstract
Reports on magnetic resonance imaging findings in patients with short chain acyl -Coenzyme A dehydrogenase (SCAD) deficiency, an autosomal recessive disorder caused by mutations in the acyl-Coenzyme A dehydrogenase (ACADS), are limited. Many asymptomatic carriers of ACAD variants have also been described necessitating careful evaluation of clinical and biochemical findings for an accurate diagnosis. Here we report a an infant with short chain acyl -Coenzyme A dehydrogenase (SCAD) deficiency diagnosed based on the characteristic biochemical findings and confirmed by genetic testing. He presented with refractory seizures and neuro regression at 4 months of age. His metabolic work up revealed elevated butyryl carnitine in plasma and ethyl malonic acid in urine. Magnetic resonance imaging of the brain showed cortical and basal ganglia signal changes with cortical swelling. Serial scans showed progression of the lesions resulting in cystic leukomalacia with brain atrophy. Exome sequencing revealed a novel homozygous nonsense variation, c.1146C > G (p.Y382Ter) in exon ten of ACADS which was further validated by Sanger sequencing. Both parents were heterozygous carriers. Follow up at 15 months showed gross psychomotor retardation and refractory seizures despite being on optimal doses of anti-epileptic medications, carnitine and multivitamin supplementation. This report expands the phenotypic and genotypic spectrum of SCAD deficiency.Entities:
Keywords: ACAD; Basal ganglia; Cystic leukomalacia; MRI; Short chain acyl -coenzyme A dehydrogenase (SCAD) deficiency
Mesh:
Substances:
Year: 2017 PMID: 28374236 DOI: 10.1007/s11011-017-0005-5
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.584